Related Experiment Video
Updated: May 3, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
7.0K
[A molecular classification system for anaplastic glioma]
Hai-hui Jiang1, Xiao-hui Ren1, Zhe Zhang1
1Department of Neurosurgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100500, China.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]
|February 7, 2014
Summary
A new molecular classification for anaplastic gliomas improves prognosis prediction. Patients with 1p/19q co-deletion, IDH1 mutation, or MGMT methylation show better survival, guiding personalized treatment strategies.
Area of Science:
- Neuro-oncology
- Molecular pathology
- Cancer genomics
Context:
- Anaplastic gliomas are heterogeneous brain tumors with variable prognoses.
- Accurate classification is crucial for effective treatment planning and patient management.
- Existing histological classifications do not fully capture the molecular underpinnings of these tumors.
Purpose:
- To develop and validate a novel molecular classification system for anaplastic gliomas.
- To correlate molecular biomarkers (1p/19q, IDH1, MGMT) with patient outcomes.
- To establish a more precise prognostic tool for anaplastic gliomas.
Summary:
- A study of 161 anaplastic glioma patients identified distinct molecular subtypes.
- Anaplastic oligodendroglioma (AO) showed significantly better progression-free survival (PFS) and overall survival (OS) than anaplastic oligoastrocytoma (AOA) and anaplastic astrocytoma (AA).
- Reclassification of AOA into AOA1 (with 1p/19q co-deletion, IDH1 mutation, and/or MGMT methylation) and AOA2 (without these markers) revealed AOA1 had similar outcomes to AO, while AOA2 mirrored AA outcomes. Molecular subtypes were independent prognostic factors.
Impact:
- The proposed molecular classification system offers improved prognostic accuracy for anaplastic gliomas.
- This system aids in stratifying patients for clinical trials and tailoring therapeutic interventions.
- It facilitates a more personalized approach to managing patients with anaplastic gliomas.
